Tenax Therapeutics Faces Securities Class Action Lawsuit
A New York law firm has filed a class action against Tenax Therapeutics over alleged investor losses tied to a nearly three-year trading window.
Law firm Bronstein Gewirtz & Grossman, LLC has announced a securities class action lawsuit against Tenax Therapeutics, Inc., traded on the Nasdaq under the ticker TENX, targeting alleged damages suffered by investors who held shares during a defined period spanning roughly three years.
Investors who purchased TENX securities between November 13, 2023, and August 7, 2026, may qualify to participate in the litigation and potentially recover losses, according to the firm's announcement. The lead plaintiff deadline is set for December 28, 2026, giving affected shareholders roughly two months to come forward.
Read more Kansas City Life Insurance Posts Lower Q3 2026 Earnings →
Class action securities suits of this type typically allege that a company or its executives made materially false or misleading statements that artificially inflated the stock price, causing harm to investors who bought shares at elevated levels. The announcement did not detail the specific allegations underpinning the Tenax case, but the multi-year class period suggests the claims may involve conduct or disclosures spanning an extended timeframe.
Tenax Therapeutics is a clinical-stage biopharmaceutical company, a sector where investor losses tied to clinical trial outcomes or regulatory decisions frequently give rise to securities litigation. Shareholders who believe they suffered losses during the specified window are encouraged by the firm to contact counsel ahead of the court deadline to evaluate their options.
Continue reading at All Financial Services & Investing.
